Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities

Richard Radun, BSc¹  Michael Trauner, MD¹

¹Department of Internal Medicine III, Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria

Semin Liver Dis 2021;41:461–475.

Address for correspondence Michael Trauner, MD, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria (e-mail: michael.trauner@meduniwien.ac.at).

Abstract
Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent cause of liver disease, increasingly contributing to the burden of liver transplantation. In search for effective treatments, novel strategies addressing metabolic dysregulation, inflammation, and fibrosis are continuously emerging. Disturbed bile acid (BA) homeostasis and microcholestasis via hepatocellular retention of potentially toxic BAs may be an underappreciated factor in the pathogenesis of NAFLD and nonalcoholic steatohepatitis (NASH) as its progressive variant. In addition to their detergent properties, BAs act as signaling molecules regulating cellular homeostasis through interaction with BA receptors such as the Farnesoid X receptor (FXR). Apart from being a key regulator of BA metabolism and enterohepatic circulation, FXR regulates metabolic homeostasis and has immune-modulatory effects, making it an attractive therapeutic target in NAFLD/NASH. In this review, the molecular basis and therapeutic potential of targeting FXR with a specific focus on restoring BA and metabolic homeostasis in NASH is summarized.

Keywords
► NAFLD
► FXR
► bile acids
► microcholestasis

Nonalcoholic fatty liver disease (NAFLD) has reached a global prevalence of approximately 25% and comprises a disease spectrum in the absence of secondary causes such as consumption of relevant amounts of alcohol.¹⁻⁵ The spectrum ranges from isolated hepatic steatosis, defined as lipid droplets present in the cytoplasm of more than 5% of hepatocytes,⁶ over progression to nonalcoholic steatohepatitis (NASH) in about one out of four patients with additional signature histopathological changes including hepatocyte ballooning and inflammation driving fibrogenesis, to liver cirrhosis and hepatocellular cancer (HCC).⁷,⁸ Its close relationship with central obesity, type 2 diabetes mellitus, insulin resistance, and dyslipidemia has contributed to the concept of NAFLD being the hepatic manifestation of the metabolic syndrome⁹ and resulted in the recent proposal of an overarching description termed metabolic (dysfunction)-associated fatty liver disease (MAFLD).¹⁰,¹¹ This also reflects efforts to make a “positive” diagnosis similar to other liver diseases which does not rely on exclusion of other causes. In line with the metabolic association, several studies have found a strong correlation between MAFLD/NAFLD and cardiovascular disease (CVD), chronic kidney disease (CKD), as well as other extrahepatic metabolic manifestations. For instance, presence of hepatic steatosis has been found to increase the risk for type 2 diabetes mellitus by approximately twofold and purports to be an independent driver for CVD additive to other risk factors.⁵,¹²,¹³ Moreover, a significant association with CKD has been reported, persisting even after correcting for other known CKD risk factors.¹² Last but not least, NAFLD also significantly impairs quality of life, in particular including fatigue and even occurrence of pruritus,¹⁴–¹⁶ a fact which may be
underappreciated compared with liver disease of other etiology. Importantly, NAFLD/NASH has become a major cause of HCC and to date, the second leading cause for liver transplantation, further emphasizing the need for effective and sustained treatment options.\textsuperscript{17–21}

Recently elevated bile acid (BA) levels have received increasing attention as prognostic signature in NASH,\textsuperscript{22–25} although the mechanisms underlying this observation are still poorly understood. In addition to their traditional perception as chemical detergents which facilitate dietary fat absorption, BAs have important signaling functions via their nuclear receptor Farnesoid X receptor (FXR) and other G-protein coupled receptors (e.g., Takeda G-protein coupled receptor [TGR5]) on their own as well as lipid/glucose metabolism and inflammation.\textsuperscript{24} The molecular alterations that occur in lipid metabolism of hepatocytes during NAFLD/NASH development are summarized in Fig. 1 (further reviewed in Arab et al\textsuperscript{26}). Given the central role of BAs and their receptors in controlling key aspects of NASH pathogenesis, modulation of BA-related pathways holds

**Fig. 1** Molecular alterations in liver microenvironment during NASH development. Hepatic steatosis results from overabundance of flux of nonesterified free fatty acids (FFAs) from hypertrophic white adipose tissue (WAT) as a result of increased lipolysis due to insulin resistance. Hepatic de novo lipogenesis (DNL) and dietary fat consumption further contribute, although to a lesser extent, to the development of hepatic steatosis. Due to its peculiar chemical structure, dietary fructose acts directly as a lipogenic substrate in the liver therefore driving DNL through sterol-responsive element-binding protein 1c (SREBP1-c) and liver X receptor (LXR) via acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) as key enzymatic steps. Upon exceeding the hepatic lipid storage capacity, this triggers a FFA overload leading to mitochondrial dysfunction, ER stress via inositol-requiring enzyme 1 (IRE-1), X-box binding protein 1 (XBP-1), and protein kinase RNA-like endoplasmic reticulum kinase (PERK) as well as apoptosis through c-Jun N-terminal kinase (JNK) and nuclear factor kappa-B (NF-kB) signaling. This lipotoxic stress response subsequently activates Kupffer cells involving damage-associated molecular patterns (DAMPs) leading to upregulation of proinflammatory markers such as tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), interleukin 6 (IL6), and monocyte chemotactic protein 1 (MCP-1) as well as activation of hepatic stellate cells (HSCs) through transforming growth factor-\(\beta\) (TGFb) and Sonic hedgehog (SHH) signaling, leading to development of lobular inflammation and fibrosis, respectively. These metabolic perturbations are associated with profound changes in BA metabolism in NASH patients where microcholestasis encompassing molecular but also structural alterations as a result of increased pericentral biliary pressure leading to dilatation and reduced connectivity of the bile canalicular (BC) network\textsuperscript{112} (lower panel). Figure created with BioRender. BA, bile acid; NASH, nonalcoholic steatohepatitis.
promise in therapeutically managing NASH.\textsuperscript{22,23,25} This review provides a summary of the pathophysiological rationale and therapeutic opportunities of targeting FXR in NASH.

**Nuclear Receptor FXR as Central Mediator of BA Signaling in Regulation of Metabolism, Inflammation, and Fibrosis**

In the liver, cholesterol from plasma or endogenous synthesis is enzymatically processed to primary BAs such as cholic acid (CA) or chenodeoxycholic acid (CDCA) which form glycine or taurine conjugates followed by active excretion at the canalicular membrane via bile salt export pump (BSEP/ABCB11) into bile and storage in the gallbladder.\textsuperscript{27} Upon food digestion, BAs are delivered after contraction of the gallbladder to the duodenum where one of their major functions entails micelle formation for facilitated absorption of fat-soluble substances (e.g., dietary lipids, fat soluble vitamins A, D, E). The majority of BAs (95\%) is actively reabsorbed involving absorption through apical sodium-dependent BA transporter (ASBT/SLC10A2), transport across the enterocyte via ileal BA-binding protein (IBABP) and followed by basolateral excretion by organic solute transporter (OSTα/β) into portal blood. The remaining BAs are metabolized by resident gut microbiota in the colon resulting in deconjugation and dehydroxylation with formation of secondary BAs such as deoxycholic acid (DCA) and lithocholic acid which can then passively re-enter the enterohepatic circulation so that only a minor fraction of approximately 0.2–0.6 g/d (~3–5\% of daily synthesis) is lost in the feces.\textsuperscript{28} To complete the enterohepatic cycle, BAs are very efficiently removed from portal blood at the basolateral membrane of hepatocytes by Na\textsuperscript{+}-taurocholate cotransporting polypeptide (NTCP/SLC10A1) and organic-anion-transporting polypeptide (OATP/SLCO) family members.

In addition to its function as a facilitator of intestinal lipid absorption, bile is a major way of clearance for various exo- and endogenous substances. From their chemical structure, BAs are amphiphilic detergents and therefore potentially cytotoxic, thus requiring a highly efficient molecular machinery to maintain intracellular BA concentrations in a nontoxic range. BA homeostasis is maintained through a negative feedback loop encompassing inhibition of BA uptake and synthesis as well as promotion of BA excretion and detoxification (reviewed in Hofmann\textsuperscript{29}). Toxicity from intracellular BAs involves induction of apoptosis, activation of proinflammatory pathways, and necrotic changes in a concentration-dependent manner.\textsuperscript{30} BAs are able to directly induce an inflammatory signal in hepatocytes reflected by increased cytokine expression as well as upregulation of adhesion molecules.\textsuperscript{31} In response to secretion of these proinflammatory mediators, immune cells such as neutrophils or macrophages are recruited and activated, further aggravating the inflammatory response in the liver.\textsuperscript{31,32}

Over the recent years, BAs in nontoxic concentrations have been shown to exert signaling functions for key metabolic and homeostatic processes such as self-regulation of BA metabolism, energy balance, and liver injury mechanisms including inflammation, fibrosis, apoptosis, and tumor development.\textsuperscript{27,33–35} These regulatory properties of BAs derive from their intrinsic ability to act as ligands for a range of receptors including nuclear receptors FXR, constitutive androstane receptor, pregnane X receptor, and vitamin D receptor as well as membrane receptors TGR5, α5β1 integrin, epidermal growth factor receptor, and sphingosine-1-phosphate receptor 2.\textsuperscript{36–39} Upon binding of BAs to FXR, the FXR–retinoid X receptor heterodimer complex is activated resulting in induction of the transcriptional repressor small heterodimer partner (SHP) which in turn down-regulates the BA synthetic key enzymes cytochrome P450 7A1 (CYP7A1) and cytochrome P450 8B1 (CYP8B1) by inhibiting their transactivators liver receptor homolog-1 and hepatocyte nuclear factor 4, molecular changes which collectively result in repression of BA synthesis.\textsuperscript{40} Apart from controlling BA synthesis, FXR activation also increases biliary BA excretion by upregulating expression of canalicular transporters BSEP as well as multidrug resistance protein 3 (MDR3/ABC4) and ATP-binding cassette subfamily G members 5 and 8 (ABCG5/G8) for accompanying phospholipid and cholesterol efflux, respectively.\textsuperscript{41,42} Concurrently, FXR activation results in repression of the uptake system NTCP via induction of SHP.\textsuperscript{43} In enterocytes, resorption of BAs leads to increased expression of FXR downstream targets including SHP, OSTα/β, fibroblast growth factor factor 19 (FGF19) and IBABP. Elevated levels of IBABP and OSTα/β result in higher vector efficiency and excretion of BAs into the portal venous system, while SHP directly downregulates ASBT expression thereby restricting intestinal BA reabsorption.\textsuperscript{44,45} Furthermore, induction of intestinal FGF19 (Fgf15 in mice) leads to activation of hepatic fibroblast growth factor receptor 4 (FGFR4)/β-Klotho downregulating CYP7A1 gene expression through the c-Jun N-terminal kinase signaling pathway.\textsuperscript{46} Taken together, FXR functions as an intestinal and hepatic BA sensor and provides elaborate negative feedback and feedforward mechanisms to uphold physiological BA homeostasis while preventing toxic BA concentrations.

Apart from this regulatory function in BA homeostasis, FXR signaling is involved in lipid and glucose metabolism (reviewed in Chávez-Talavera et al.\textsuperscript{47}). Mice deficient of FXR present with significantly increased serum and hepatic triglyceride, cholesterol, and free fatty acid (FA) levels.\textsuperscript{48} In line, upon administration of an FXR agonist, wild-type (WT) mice but not FXR-knockout (FXR-KO) mice exhibit decreased serum cholesterol, triglyceride, free FA, and lipoprotein levels.\textsuperscript{49} Activation of FXR and subsequent upregulation of SHP result in repressing sterol-regulatory element-binding protein 1c (SREBP-1c) which limits hepatic de novo lipogenesis (DNL).\textsuperscript{50} FXR-dependent elimination of serum lipoproteins results from modulation of expression of target genes such as scavenger receptor B1, very low density lipoprotein (LDL) receptor, Syndecan-1, ApoCII/III as coactivators/inhibitors of lipoprotein lipase, and FA translocase (FAT/CD36).\textsuperscript{51} On the other hand, FXR promotes β oxidation by activation of peroxisome-proliferator-activated receptor (PPARα).\textsuperscript{52} Correspondingly, FXR-mediated FGF15/19 signaling
was shown to induce β-oxidation in mitochondria via reduction of malonyl-CoA by repression of acetyl-CoA carboxylase (ACC2). Regarding systemic effects, it has been shown that treatment with primary BA CDCA improves hypertriglyceridemia through an FXR- and SHP-dependent mechanism. In line, disruption of BA reabsorption through use of BA sequestrants leads to increased biosynthesis of BAs from cholesterol thereby efficiently counteracting hypercholesterolemia. Additionally, reduced plasma glucose levels and a trend toward lower HbA1c have been observed in cholestyramine-treated diabetic patients. At the same time, a common adverse effect of resin treatment lies in aggravation of hypertriglyceridemia, further underlining the role of BAs in triglyceride and cholesterol metabolism. The signaling role of BAs in enterohepatic circulation with systemic metabolic effects of FXR is delineated in Fig. 2. Further studies investigating the role of FXR in glucose homeostasis showed that in line with its key role in BA and lipid metabolism, FXR-KO rodents exhibit features of hepatic and systemic insulin resistance as seen in increased fasting and fed glucose levels, decreased peripheral glucose disposal assessed by hyperinsulinemic clamp, and impaired gluconeogenesis. Appertaining to this, insulin resistance in ob/ob and db/db but not KO mice could effectively be mitigated by feeding them with an FXR agonist such as CA/GW4064. A potential mechanism by which FXR
activation modulates glucose metabolism appears to be repression of key enzymes necessary for gluconeogenesis such as phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, and fructose-1,6-bisphosphatase. By triggering FGF15/19, activation of FXR stimulates glycogen synthesis and therefore decreased hepatic glucose output and plasma levels. Furthermore, while activation of FXR in the terminal ileum inhibits glucagon-like peptide (GLP-1) secretion through decreased expression of carbohydrate-responsive element-binding protein and impaired glycolysis, BA signaling via TGR5 plays an important role in glucose homeostasis by inducing secretion of GLP-1 from enteroendocrine L-cells in the gastrointestinal tract, reflective of its therapeutic potential in NASH and obesity (reviewed in Chávez-Talavera et al. 67). These potentially opposing effects might explain differential actions of BA-based therapies and FXR ligands in glucose homeostasis and need to be addressed more mechanistic detail. In addition to its qualities as a controller of enterohepatic circulation, FXR plays a major role in modification of inflammation. Anti-inflammatory mechanisms of FXR can be attributed to stabilization of the nuclear corepressor NCOR leading to repression of nuclear factor kappa B and downstream inflammatory genes such as tumor necrosis factor-α, interleukin 6, inducible nitric oxide synthase, and cyclooxygenase 1. INT767, a dual agonist for both FXR and TGR5, has been shown to improve liver histology and reduce proinflammatory cytokine expression in db/db mice as well as inducing a gene expression shift toward alternatively activated macrophages. 64

In addition to inflammation, FXR has important impact on fibrogenesis as another key step in the progression of NASH. Although FXR is not expressed to significant amounts in hepatic stellate cells (HSCs), pharmacological activation of FXR was able to ameliorate thioacetamide-induced fibrosis and portal hypertension by counteracting inflammation and reconstitution of endothelial nitric oxide synthase activity in sinusoidal endothelial cells. Since fibrosis drives activation of HSC and therefore hepatic fibrosis, administration of FXR agonist obeticholic acid (OCA) may counteract fibrosis in rodents by blunting expression of proinflammatory cytokines in hepatocytes and Kupffer cells. Furthermore, nonsteroidal FXR agonist PX20606 (precursor of clinically tested compound Cilofexor) ameliorated liver fibrosis and sinusoidal dysfunction in experimental models of noncirrhotic and cirrhotic portal hypertension. 65-69 69 Although these findings provide at least in part the mechanistic basis for clinical efficacy of FXR agonists in NASH fibrosis, the antifibrotic effects of OCA in recent clinical trials appear to be less pronounced (discussed below). Apart from obvious reasons such as species differences and variable duration of the fibrogenic insults, another possible explanation may be SUMOylation of FXR. This phenomenon leads to poor responsiveness to FXR agonist OCA, while upon co-treatment with SUMOylation inhibitors, the antifibrotic effect of FXR activation could be recovered via stabilizing of HSC lipid droplets by inducing Perilipin 1. 70

In addition to their pleiotropic effects on the liver, BAs undergoing enterohepatic circulation also affect the gut microbiome and vice versa. As such, BAs through their deterrent properties act as antimicrobial agents by disrupting bacterial membrane integrity as well as by inducing genes involved in antibacterial defense through FXR, therefore inhibiting bacterial translocation. 71-73 For instance, treatment of bile duct-ligated mice with naturally occurring BAs or OCA led to improved intestinal barrier, intestinal inflammation, and decreased bacterial translocation. 74,75 Accordingly, in murine models of chemically induced colitis, FXR agonistic treatment led to reduced intestinal inflammation and improved epithelial membrane integrity. 76

On the other hand, microbiota metabolize BAs through introducing chemical modifications such as deconjugation and dehydroxylation, therefore altering their signaling properties. As such microbial generation of secondary BA isoDCA through modulation of intestinal FXR leads to increased differentiation of regulatory T cells, therefore underlining the notion of BA as immunomodulatory mediators. 77 Microbial processing of BAs not only involves activation but also inactivation of FXR. 78,79 For instance, in germ-free mice, accumulation of taurine-conjugated muricholic acid (Tα/βMCA) inhibits intestinal FXR and downstream Fg15 expression. In line, treatment of rodents with Tempol, which is an antioxidant reducing bile salt hydrolase activity, improves diet-induced obesity potentially through accumulation of intestinal TαMCA, similar to what is observed in intestine-specific FXR-deficiency models. 81 Mechanistically, intestinal inhibition of FXR leads to reduced biosynthesis of ceramides which have been linked to insulin resistance and inflammation in NASH. 82 Furthermore, ceramides induce lipogenesis through upregulation of SREBP1c and have therefore been implied as causal factors in NAFLD. 83 A direct comparison of germ-free and conventionally raised WT and FXR-KO mice revealed that diet-induced obesity and the accompanying systemic phenotype are promoted and transmissible by gut microbiota through FXR signaling. In line, in a study investigating gut microbiota of twins discordant for obesity, it was shown from transplantation of fecal microbiota to germ-free mice that lean twins had an FXR antagonistic microbial signature, supporting the concept of targeting the gut microbiome and intestinal FXR for treatment of NAFLD. 85

Changes in BA Homeostasis and Microcholestaesis in NASH

Across their disease spectrum, patients with NAFLD exhibit alterations in BA homeostasis and their BA metabolome. A range of studies has revealed that serum BA concentrations are increased in NASH patients compared with healthy controls. 24,86-88 Higher serum BA concentrations in NASH were observed in both fasting and postprandial states. 89,90 The elevations of BA levels could be largely attributed to increased primary BAs and BA levels correlated with increasing NAFLD activity score (NAS) and fibrosis stage. 87 In line, 7α-hydroxy-4-cholesten-3-one (C4) and CYP7A1 as markers of BA synthesis as well as serum BA levels correlated with disease severity in NASH patients. 88,91
In addition to serum BA levels, also their composition changes in NASH. More specifically, the ratio of conjugated to unconjugated BAs was elevated in NASH patients and an increased proportion of CA compared with CDCA could be detected which further contributes to mitigation of FXR signaling since CA is a weaker ligand than CDCA. In line, gas-liquid chromatography of liver tissue from NASH patients revealed an increase in total BAs with CA and the ratio of trihydroxylated to dihydroxylated BAs being strongly correlated to inflammatory activity.

However, it is not clear whether these changes can be attributed to underlying metabolic changes (i.e., insulin resistance and obesity) rather than NASH per se. For instance, insulin-resistant patients were shown to have a shift in BA profile toward 12α-hydroxylated BAs, which correlated with plasma triglyceride levels. Moreover, comparison of obese patients either with biopsy-proven NASH or with healthy livers revealed that BA alterations in these patients are associated with concomitant insulin resistance but did not depend on presence of NASH.

The exact pathogenetic mechanism underlying these alterations of BA levels and composition in NASH patients still remains unclear and several options can be considered. In line with a mechanistic correlation to obesity and insulin resistance, multiple rodent models of diabetes exhibit altered BA metabolism (reviewed in Watkins and Sanders). As such, in streptozotocin-treated rats, decreased bile flow despite increased secretion of BAs together with increased BA levels in serum support the concept that alterations of BA levels in NASH may reflect underlying insulin resistance rather than the associated severity of liver disease.

Paradoxically, FXR-FGF19 signaling—normally repressing BA synthesis—is impaired despite elevated BA levels, possibly reflective of underlying "FXR and/or FGF19 resistance" in NASH. Indeed, preclinical NASH models revealed partial resistance to FXR activation, reflected by transcriptional down-regulation of SHP with consequent up-regulation of CYP7A1. Furthermore, as a reflection of impaired hepatic FXR activation, increased CYP7A1 expression could be observed in NASH patients while controversial results on BSEP and SHP expression have been reported. NASH patients exhibit elevated cholesterol levels and increased activity of HMG-CoA reductase (HMGR) correlating with histologic features of NASH, integrating cholesterol levels to the concept of lipotoxicity. In line, upregulated synthesis of free cholesterol may contribute to increased BA synthesis resulting from dysregulated FXR signaling. In accordance with these findings, free FAs have been reported to repress FXR-induced SHP-signaling, therefore leading to increased BA synthesis and uptake potentially contributing to hepatocellular injury. Similarly, expression of downstream target of intestinal FXR activation FGF19 is reduced in patients with NAFLD and NASH and impaired hepatic repression of BA synthesis in insulin-resistant patients was observed. This inverse relationship was correlated with severity of liver histology in NAFLD patients, therefore highlighting the potential of serum FGF19 levels as a biomarker for NAFLD. Hepatic FXR activation can in part be assessed by measuring C4, an intermediate step in BA synthesis from cholesterol. As such, C4 is robustly elevated in NAFLD patients, supporting the notion of increased BA synthesis due to lower FXR activity. In line, increased C4 levels have been associated with fibrosis score in NASH.

Moreover, changes in BA levels and composition may also reflect intestinal dysbiosis in NASH. Human fecal analyses revealed increased levels of CA, CDCA, and total BA in stool of NASH patients compared with healthy controls. Furthermore, the obesity-induced BA and gut microbial metabolite DCA have been found to induce a senescence-associated secretory phenotype in HSC thereby facilitating development of liver cancer. Changes in blood microbiota profiles as a reflection of dysbiosis and decreased ratios of secondary to primary BAs in serum suggesting an impaired ability to convert primary BAs have been reported to correlate with fibrosis in obese patients.

In addition to increased BA synthesis and altered intestinal/microbial BA metabolism, impaired excretion of BAs and other biliary constituents may contribute to the pathogenesis of NAFLD, consistent with the concept of (micro)cholestasis in NASH. Mechanistically, biliary BA excretion can be characterized by determining bile flow and intrahepatic canalicular bile pressure. Biliary pressure constitutes a hydrostatic force which was shown to disrupt bile canaliculi integrity, therefore contributing to hepatocyte necrosis and bile infarcts. In addition, mechanosensing in the bile canaliculi network either directly through pressure sensors localized on cholangiocytic primary cilia or indirectly through biliary hydrostatic pressure opposing the osmotic gradient has been proposed as a mechanism to induce a Ca²⁺ and cAMP-dependent signaling response leading to adaptive changes in the ductular network. Albeit cholestasis not generally considered a feature of NASH, elevated gamma-glutamyl transferase (GGT) levels—which have thus far been largely attributed to oxidative stress—in concert with elevated BA levels and altered BA composition point to the fact that there may be a cholestatic component in the pathogenesis of NASH. Impaired BA excretion and transport could result in altered signaling as well as accumulation of potentially toxic BAs and other biliary constituents, serving as a potential additional hit to NASH progression. Indeed, three-dimensional spatially resolved imaging of human NASH livers revealed profound topological defects in the bile canaliculi network, consistent with an underlying microcholestatic state (see Fig. 1). Computational modeling of bile flow in these patients predicted higher pericentral biliary pressure which was correlated with GGT levels as a typical serum biochemical finding in NAFLD/NASH, underscoring the concept of microcholestasis. Hepatocyte morphometry revealed increased number and size of lipid droplets pericentrally correlating with disease progression and potentially contributing to apical protein trafficking disruption. More specifically, dipetidyl peptidase 4 which follows a transcytotic route for apical expression was mislocalized while multidrug resistance-associated protein (MRP2) and BSEP localization remained intact. Contrasting this finding and in line with preclinical...
studies in rodent models, altered protein trafficking and mislocalization of MRP2 and MRP3 have been found in NASH patients, further substantiating the concept of microcholangitis in NASH. Under cholestatic conditions, hepatocellular transport systems undergo adaptive changes mainly through FXR activation, resulting in downregulation of the BA uptake transporter NTCP, whereas compensatory basolateral efflux increases through OStoβ, MRP3, and MRP4 bypassing impaired canalicular excretion. More precisely, decreased BA-independent bile flow coinciding with downregulation of hepatic MRP2 and OATP2 has been reported while BSEP and NTCP expression remained unchanged, reflecting an impaired hepatobiliary transport capacity. Interestingly, mice lacking the canalicular BA export pump BSEP display impaired mitochondrial FA oxidation as well as reduced white adipose tissue mass. In line, challenging these mice with dietary models of hepatic steatosis leads to attenuation of hepatic lipid accumulation despite worsened inflammation, potentially through impaired FXR and PPARα signaling. Additionally, genetic polymorphisms of ABCB11, the gene encoding for human BSEP, have been correlated to higher triglyceride and cholesterol levels as well as body mass index. However, the exact mechanism of microcholangitis as well as addressing the topological and molecular alterations of the hepatobiliary network in NASH is still poorly understood and requires further interrogation. Even so, these findings support the concept to apply empirically used or novel anticholestatic therapies such as ursodeoxycholic acid (UDCA) and norUDCA or FXR agonists, respectively, in NASH (see the following section).

Targeting FXR in Microcholangitis of NASH and Beyond

Due to the key role of FXR in regulating not only BA homeostasis, but also glucose and lipid metabolism, as well as inflammation and fibrosis, pharmacological targeting of FXR has become a promising strategy for treating NAFLD/NASH. In line with the key role of FXR in maintaining biliary homeostasis, FXR ligands have first been developed as therapy for cholestatic liver diseases. Since BAs are increasingly conceived as important biomarkers of NAFLD and microcholangitis has emerged as a feature of NASH, modulating FXR activity as a key regulator of BA homeostasis may be a key asset or at least important added benefit for treating NASH (see Fig. 2).

In multiple preclinical models, FXR agonism led to resolution of features of steatohepatitis through its metabolic and anti-inflammatory effects. Steroidal FXR agonists such as OCA but also natural ligands such as CA and CDCA have been shown to improve insulin resistance and steatosis in obese rats, as well as ameliorate inflammation and fibrosis in mouse models of NASH. As another example, administration of nonsteroidal FXR agonist WAY-362450 ameliorated steatohepatitis and fibrosis in mice fed a methionine-choline-deficient diet in an FXR-dependent fashion. Additionally, FXR agonism reduces vascular inflammation and plaque formation in rodent models of atherosclerosis, highlighting its therapeutic potential on CVD associated with NAFLD/NASH. Moreover, administration of OCA in rodent models of CKD led to attenuation of renal injury and counteracted diabetic nephropathy. Taken together, FXR agonism may not only be a promising target for treatment of NASH, but also for associated cardiometabolic comorbidity, warranting further investigations.

Several clinical trials currently investigate the effects of FXR ligands in NAFLD/NASH and most progress has so far been made for OCA as first in class steroidal FXR agonist. In a small proof-of-concept phase II study testing OCA in diabetic patients with NAFLD, administration of either 25 or 50 mg OCA once daily over 6 weeks improved insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp as well as liver enzymes (GGT, alanine aminotransferase [ALT], aspartate aminotransferase [AST]), findings which were associated with a modest reduction in noninvasive fibrosis parameters (Enhanced Liver Fibrosis [ELF] score) in the 25-mg OCA group compared with placebo. Additionally, OCA treatment increased FGF19 levels in a dose-dependent manner as well as decreasing C4 levels and levels of total endogenous BAs, reflecting target engagement and giving mechanistic insight into the regulation of insulin resistance in NASH patients. A subsequent large multicenter phase Ib study (FLINT—FXR Ligand Obeticholic Acid in NASH Treatment) enrolling 283 patients revealed effectiveness of 25 mg OCA treatment in NASH patients compared with placebo after 72 weeks. OCA treatment resulted in a significant improvement in the primary histological endpoint, defined as a decrease in NAS of at least two points with no worsening of fibrosis, as compared with placebo, while no significant impact on overall resolution of NASH was observed. Again, levels of ALT, ASAT, and GGT significantly improved upon OCA treatment while serum levels of alkaline phosphatase (known to be upregulated by FXR) increased. However, OCA treatment led to an unfavorable lipid profile as reflected by increased levels of serum LDL and decreased levels of serum high-density lipoprotein (HDL). In addition, development of moderate to severe pruritus was more common in the OCA-treated group compared with placebo. Surprisingly, measurement of hepatic insulin resistance using the homeostasis model of assessment (HOMA-IR) showed an increase in insulin resistance despite weight loss during OCA treatment, both of which reverted back after treatment discontinuation. This effect on insulin resistance contrasting the findings from the previous proof-of-concept phase II study in diabetics might be in part attributed to different methodology in assessing insulin resistance as well as decentralized insulin measurements.

Furthermore, in a recent interim analysis of the subsequent multicenter phase III study (REGENERATE—Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment), statistically significant improvement of fibrosis was seen in 12% in patients receiving placebo compared with 18% in patients...
receiving 10 mg OCA and 23% in patients receiving 25 mg OCA, while the endpoint for resolution of NASH was not met.\textsuperscript{137} Side effects of OCA treatment again were increased LDL cholesterol levels at the expense of HDL cholesterol and mild to moderate pruritus in a dose-dependent manner. With reduction of NASH activity and fibrosis on one hand and features of dyslipidemia on the other, the overall clinical benefit of OCA treatment in terms of cardiometabolic comorbidity or all-time mortality is the subject of currently ongoing studies.

With the initial intention to avoid adverse effects such as LDL increase or occurrence of pruritus, various nonsteroidal synthetic FXR agonists have been developed and several compounds are currently tested in phase II clinical trials.\textsuperscript{138} Administration of Cilofexor (formerly known as GS-9674, follow-up compound to Px-102/Px-104) in noncirrhotic NASH patients revealed reduction of hepatic steatosis as measured by magnetic resonance imaging (MRI-PDFF) and decreased levels of GGT, C4, and primary BA, while no changes were observed for noninvasive parameters of liver fibrosis using ELF, transient elastography, and magnetic resonance elastography. While the serum lipid profile did not change significantly upon Cilofexor treatment, dose-dependent occurrence of pruritus was observed.\textsuperscript{139}

In another trial, Cilofexor, ACC inhibitor Firsocostat, and apoptosis-signal regulating kinase 1 inhibitor Selonsertib have been tested alone or in a dual-drug combination strategy in a phase Ib trial in NASH patients for 48 weeks.\textsuperscript{140} None of the treatment arms achieved significant changes compared with placebo for the primary endpoint (≥ 1-stage improvement in fibrosis without worsening of NASH). However, significant improvements in biochemical and noninvasive fibrosis parameters, ≥ 2-point NAS reductions and its subcomponents, as well as a significant shift of advanced (F3/ F4) to nonadvanced fibrosis stages using a machine learning-based algorithm, were observed with the combination of Cilofexor and Firsocostat compared with placebo. Again, occurrence of pruritus has been reported more often in Cilofexor-treated patients.

Another non-BA FXR agonist called Tropifexor (LJN452) has been successfully tested in multiple preclinical NASH models.\textsuperscript{141,142} In healthy volunteers, administration of Tropifexor was well tolerated and did not lead to significant alterations in the plasma lipid profile encouraging further studies.\textsuperscript{143} Recent interim results from a currently undergoing phase II clinical trial in NASH patients (FLIGHT-FXR: NCT02855164) revealed robust and dose-dependent reduction of ALAT, GGT, hepatic fat fraction, and body weight in patients receiving either 140 or 200 µg Tropifexor over 12 weeks.\textsuperscript{144} Despite a significant reduction of collagen proportional area in the 200-µg-treated group, neither of the Tropifexor groups showed significant difference in terms of histological improvement of NASH or fibrosis stage as a predefined endpoint.\textsuperscript{144} Regarding adverse events, a dose-related increase in LDL cholesterol and an association with mild pruritus were reported. Notable changes in LDL cholesterol levels appear to generally increase in therapies that reduce hepatocellular BA levels through accumulation of total cholesterol which impairs SREBP2 signaling, leading to downregulation of LDL receptor (LDLR) expression and therefore, increased serum LDL cholesterol.\textsuperscript{145} Collectively, these data also raise the question whether pruritus stems from FXR agonism directly rather than from elevated levels of BAs or BA derivatives and drives the necessity for comprehensive therapeutic strategies to manage adverse effects in FXR agonist treatment including pruritus.\textsuperscript{146} In addition to Cilofexor and Tropifexor, multiple other nonsteroidal FXR agonists are currently under investigation for treatment of NAFLD/NASH (reviewed in Gege et al\textsuperscript{138}).

As another strategy in the treatment of NASH, recent studies have turned toward FGF19 analogues. Being a downstream target of intestinal FXR activation, FGF19 has been proposed to reduce hepatic lipid content while potentially sidestepping adverse effects of direct FXR agonism. Notably engineered FGF19 analogues show distinct dissociation of metabolic from proliferative potentially procarcinogenic effects by blunting the signal transducer and activator of transcription 3-activating function of the naturally occurring protein.\textsuperscript{147} In line, preclinical models testing a synthetic and nontumorigenic FGF 19 analogue, Aldafermin/NGM282 (formerly known as M70), were even able to prevent tumor formation.\textsuperscript{148} Additionally, Aldafermin/NGM282 treatment in humans led to a dose-dependent enrichment of BA-sensitive commensal microbe Veillonella, which correlated to physical performance-enhancement through its ability to degrade exercise-induced lactate to propionate.\textsuperscript{149,150}

An interim analysis investigating 1 or 3 mg Aldafermin/NGM282 treatment in NASH patients revealed a significant histological response (defined as > 2-point improvement of NAS without worsening of fibrosis or > 1 point improvement in fibrosis without worsening of NASH) in 50 and 68% after 12 weeks treatment, respectively.\textsuperscript{151} Although Aldafermin/NGM282 treatment for 24 weeks also showed a robust decrease in liver fat content (measured by MRI-PDFF) as well as serum transaminases and BA and C4 levels, no significant impact on histological assessment of liver fibrosis or NASH resolution could be observed at this extended time point.\textsuperscript{152} Interestingly, Aldafermin/NGM282 treatment over 12 weeks also improved noninvasive markers of fibrosis significantly in patients with primary sclerosing cholangitis independent of biochemical improvement of cholestasis, suggesting potential direct antifibrotic effects.\textsuperscript{153} Adverse events included diarrhea, nausea, and abdominal pain as well as increased LDL-cholesterol levels which, however, could be effectively and safely counteracted by rosuvastatin administration.\textsuperscript{151,152,154,155}

Apart from the above-mentioned beneficial effects of systemic treatment to induce hepatic FXR signaling, gut-selective modulation of FXR activity has been proposed as a mechanism to target obesity and development of NAFLD. Intestinal FXR agonism counteracted diet-induced obesity, insulin resistance, and inflammation in mice through induction of FGF15 without altering hepatic FXR signaling.\textsuperscript{156} Contrasting this finding, intestinal knockout of FXR in high-fat diet (HFD)-fed mice led to ameliorated hepatic steatosis due to reduced circulation of ceramides.\textsuperscript{83}
Moreover, dietary modulation of the gut microbiome through accumulation of TßMCA resulting in intestinal FXR antagonism led to decreased ceramide levels and therefore, reduced hepatic gluconeogenesis and insulin resistance. Modulation of gut microbiota in rodents by antibiotics changes intestinal BA composition toward an intestine-specific inhibition of FXR signaling also through accumulating of TßMCA normally degraded by intact gut microbiota and leads to lower levels of circulating ceramides, therefore decreasing DNL and ameliorating hepatic steatosis. Interestingly, UDCA may be seen as a weak FXR antagonist. Indeed, in morbidly obese NAFLD patients, administration of UDCA exerted FXR-antagonistic effects as seen through upregulation of CYP7A1 impacting on BA synthesis as well as increasing SREBP2 and consequently LDLR reflecting cholesterol homeostasis in addition to promoting neutral lipid accumulation in adipose tissue and liver. In summary, opposing effects of FXR modulation in an organ/tissue-specific manner reveal novel therapeutic avenues to treat NAFLD, warranting further studies to resolve these apparent discrepant findings between the effects of FXR agonism versus antagonism.

In addition to the aforementioned effects, UDCA treatment in multiple rodent models of NASH led to resolution of liver steatosis and inflammation. Furthermore, TUDCA has been proposed as a chemical chaperone to increase the adaptive capacity of the endoplasmic reticulum (ER), therefore increasing the upregulation of CYP7A1 impacting on BA synthesis as well as increasing SREBP2 and consequently LDLR reflecting cholesterol homeostasis in addition to promoting neutral lipid accumulation in adipose tissue and liver. In summary, opposing effects of FXR modulation in an organ/tissue-specific manner reveal novel therapeutic avenues to treat NAFLD, warranting further studies to resolve these apparent discrepant findings between the effects of FXR agonism versus antagonism.

As an alternative to BA sequestrants, pharmacological inhibition of ASBT to prevent intestinal BA reuptake is being increasingly tested in models of NASH. In contrast to resin-bound BAs which activate TGR5 therefore increasing GLP-1 levels, free intestinal BAs increased by ASBT inhibition activate FXR signaling, which in turn upregulates GLP-1 secretion. Interestingly, intestinal ASBT inhibition led to increased fecal BA excretion and a shift in BA composition toward more FXR agonistic BAs in line with normalization of glucose tolerance and improvement of hepatic steatosis and NAS in HFD-fed mice. However, a recent 24-week interim analysis of a phase II trial involving ASBT inhibitor Volixibat showed that despite target affection seen by dose-dependent increase of C4 serum levels and decrease of cholesterol levels, no liver-specific therapeutic benefit could be noted. Currently, a wide range of ASBT inhibitors are explored for pediatric cholestasis, but their potential benefit for NASH remains to be determined (reviewed in Karpen et al 2014).

Finally, norUDCA, recently renamed as norucholic acid, is a side chain shortened, conjugation-resistant UDCA derivative that undergoes cholehepatic shunting therefore allowing for liver-targeted therapy in multiple liver diseases. norUDCA has been shown to elicit anti-inflammatory, anti-apoptotic, and antifibrotic effects in multiple experimental NASH models. Cholehepatic shunting is particularly beneficial in targeting ductular reaction, which is a histopathological feature typically seen in cholestatic liver injury.
but also in NAFLD.\textsuperscript{188} Ductular reaction in NASH has been associated with fibrosis development as well as the extent of hepatocytes in replicative arrest, therefore reflecting hepatocyte senescence.\textsuperscript{1,189} Additionally, cholangiocytes have been shown to be susceptible to lipopoapoptosis primarily through saturated free FAs, suggesting their engagement in the pathogenesis of NAFLD.\textsuperscript{190} Recently, a multicenter phase IIa trial investigated the effect of norUDCA in NASH revealing a dose-dependent reduction of serum ALT\textsuperscript{191} inciting a currently ongoing phase IIb study whose primary endpoint will involve histological improvement or resolution of NASH (EudraCT-Nr.:2018–003443–31). Due to the underappreciated role of microcholestasis and ductular changes in NASH, future combination therapies may need to focus on anticholestatic agents in NASH.

Conclusion and Outlook

Beyond their traditional role as detergents facilitating lipid uptake, BAs have recently emerged as important signaling molecules of controlling cellular metabolism throughout the enterohepatic system by FXR-dependent and FXR-independent pathways. The effect of FXR signaling on hepatic BA, lipid, and glucose metabolism in addition to its immunomodulatory properties holds promise for impeding development or progression of NASH. Moreover, recent findings have established the concept of microcholestasis as a key feature of NAFLD, further underlining the therapeutic potential of FXR modulation. While most preclinical and experimental NASH models have shown markedly positive results, clinical data on FXR-related and other BA-targeted treatment strategies remain promising, but rather modest. Since the mechanism of action is rather novel, particular attention has to be directed to occurrence of side effects such as dyslipidemia and pruritus and long-term safety observations. Future studies will have to show whether combination strategies with other metabolic, anti-inflammatory, and/or antifibrotic strategies result in synergistic therapeutic benefit and future studies are warranted to investigate the effect of targeting BA-related and anticholestatic pathways in NAFLD by FXR and beyond.

Main Concepts and Learning Points

- In addition to their detergent actions, bile acids (BAs) have important signaling function via the nuclear receptor FXR, which regulates their own homeostasis as well as lipid/glucose metabolism and inflammation.
- Alterations of BA homeostasis are a key pathogenetic and prognostic factor in nonalcoholic fatty liver disease (NAFLD) and its progressive variant with steatohepatitis (NASH).
- Microcholestasis is an underappreciated feature of the pathophysiology of NAFLD/NASH, which can be targeted by FXR and other BA-based therapies.
- Results from preclinical and clinical studies indicate that targeting FXR and other BA-related pathways is a promising treatment strategy for NASH.

Conflicts of Interest

Michael Trauner reports personal fees from Albireo; grants, personal fees, and other from Gilead; grants, personal fees, and other from Falk Foundation; personal fees from Novartis; grants, personal fees, and other from Intercept; grants, personal fees, and other from MSD; personal fees from Phenex; grants from Takeda; personal fees from BMS; personal fees from Boehringer Ingelheim; personal fees from BioMX; personal fees from Genfit; personal fees from Regulus; other from Abbvie; grants from Cymabay; personal fees from Shire; personal fees from Plant outside the submitted work. In addition, he has a patent Medical use of nor-UDCA (WO2006119803 and WO20099013334 licensed to Medical University of Graz.

References

1 European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD). European Association for the Study of Obesity (EASO) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(06):1388–1402
2 Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(01):328–357
3 Wong VW-S, Chan W-K, Chitturi S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-part 1: definition, risk factors and assessment. J Gastroenterol Hepatol 2018;33(01):70–85
4 Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol 2019;70(03):531–544
5 Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2019;69(06):2672–2682
6 Brunet EM, Wong VW-S, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1:15080
7 Ekstedt M, Nasr P, Kechagias S. Natural history of NAFLD/NASH. Curr Hepatol Rep 2017;16(04):391–397
8 Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis 2015;35(03):221–235
9 Vanni E, Marengo A, Mezzabotta I, Bugianesi E. Systemic complications of nonalcoholic fatty liver disease: when the liver is not an innocent bystander. Semin Liver Dis 2015;35(03):236–249
10 Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73(01):202–209
11 Eslam M, Sanyal AJ, George J. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158(07):1999.e1–2014.e1
12 Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017;66(06):1138–1153
13 Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 2021;70(05):962–969
14 David K, Kowdley KV, Unalp A, Kanwal F, Brunet EM, Schwimmer JBNASH CRN Research Group. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the
nonalcoholic steatohepatitis clinical research network. Hepatology 2009;49(06):1904–1912

15 Newton JL, Jones DEJ, Henderson E, et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008;57(06):807–813

16 Younossi ZM, Wong VW-S, Ansee QM, et al. Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient-reported outcomes. Hepatol Commun 2020;4(11):1637–1650

17 Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148(03):547–555

18 Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: disease burden, current management and future challenges. JHEP Rep 2020;2(06):100192

19 Goldberg D, Ditah IC, Saeian K, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 2017;152(05):1090.e1–1099.e1

20 Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol 2021;19(03):580.e5–589.e5

21 Holmer M, Melum E, Isorniemi H, et al. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. Liver Int 2018;38(11):2082–2090

22 Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol 2013;86(11):1517–1524

23 Yuan L, Bamba K. Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol 2015;7(28):2811–2818

24 Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology 2017;65(01):350–362

25 Schaap FG, Trauner M, Jansen PLM. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014;11(01):55–67

26 Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol 2018;13:321–350

27 Trauner M, Fuchs CD, Halibasic E, Paumgartner G. New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology 2017;65(04):1393–1404

28 Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999;159(22):2647–2658

29 Hofmann AF. The enterohpatic circulation of bile acids in mammals: form and functions. Front Biosci 2009;14:2584–2598

30 Jansen PLM, Gullab A, Vartak N, et al. The ascending pathophysiology of cholestatic liver disease. Hepatology 2017;65(02):722–738

31 Allen K, Jaeschke H, Coppel BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 2011;178(01):175–186

32 Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol 2017;66(06):1300–1312

33 Li T, Chiang JYL. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 2014;66(04):948–983

34 Chiang JYL. Bile acid metabolism and signaling. Compr Physiol 2013;3(03):1191–1212

35 Zhu C, Fuchs CD, Halibasic E, Trauner M. Bile acids in regulation of inflammation and immunity: friend or foe? Clin Exp Rheumatol 2016;34(04, Suppl 98):25–31

36 Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999;284(5418):1362–1365

37 Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284(5418):1365–1368

38 Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999;3(05):543–553

39 Studer E, Zhou X, Zhao R, et al. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology 2012;55(01):267–276

40 Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000;6(03):517–526

41 Huang L, Zhao A, Lew J-L, et al. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem 2003;278(51):51085–51090

42 Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001;276(31):28857–28865

43 Denson LA, Sturm E, Echevarria W, et al. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 2001;121(01):140–147

44 Lu TT, Makishima M, Repa JJ, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000;6(03):507–515

45 Neimark E, Chen F, Li X, Shneider BL. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 2004;40(01):149–156

46 Song K-H, Li T, Owsley E, Strom S, Chiang JYL. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009;49(01):297–305

47 Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 2017;152(07):1679.e3–1694.e3

48 Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000;102(06):731–744

49 Zhang Y, Lee FY, Herrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006;103(04):1006–1011

50 Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113(10):1408–1418

51 Fuchs CD, Traussnigg SA, Trauner M. Nuclear receptor modulation for the treatment of nonalcoholic fatty liver disease. Semin Liver Dis 2016;36(01):69–86

52 Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart J-C, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003;17(02):259–272

53 Potthoff MJ, Boney-Montoya J, Choi M, et al. FGFR5/15 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab 2011;13(06):729–738

54 Carulli N, Ponz de Leon M, Podda M, et al. Cholesteroloxycolic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial. J Clin Pharmacol 1981;21(10):436–442

55 Hashim SA, Vanallite TB. Cholestyramine resin therapy for hypercholesterolemia: clinical and metabolic studies. JAMA 1965;192:289–293
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH

56 Garg A, Grundy SM. Cholestryramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994;121(06): 416–422
57 Crouse JR III. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 1987;83(02):243–248
58 Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116(04):1102–1109
59 Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010;51(04):771–784
60 Mazuy C, Helleboid A, Staels B, Leefbvre P. Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol Life Sci 2015; 72(09):1631–1650
61 Staels B, Handelsman Y, Fonsecva V. Bile acid sequestrants for lipid and glucose control. Curr Diab Rep 2010;10(01):70–77
62 Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011;331(6042):1621–1624
63 Wang Y-D, Chen W-D, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008;48(05):1632–1643
64 McMahan RH, Wang XX, Cheng LL, et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem 2013;288(17):11761–11770
65 Fickert P, Fuchsbiehler A, Moustafa T, et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatocyte cell lines and periductal myofibroblasts. Am J Pathol 2009;175(06):2392–2405
66 Verbeke L, Farre R, Treibica J, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014;59(05):2286–2298
67 Verbeke L, Mannaerts I, Schiervera R, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep 2016;6:33453
68 Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, et al. FXR agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014;59(06):2286–2298
69 Verbeke L, Mannaerts I, Schiervera R, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep 2016;6:33453
70 Campbell C, Mckenney PT, Konstantinosky D, et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 2020;581(7809):475–479
71 Gonzalez FJ, Jiang C, Patterson AD. An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. Gastroenterology 2016;151(05):845–859
72 Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol 2018;15(02):111–128
73 Sayin SI, Wahlstrom A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013;17(02):225–235
74 Li F, Jiang C, Krausz KW, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 2013;4:2384
75 Pagadala M, Kasumov T, McCullough AJ, Zein NN, Kirwan JP. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab 2012;23(08):365–371
76 Jiang C, Xie G, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015;125(01):386–402
77 Parsaës A, Sommer N, Sommer F, et al. Microbiota-induced obesity requires farnesoid X receptor. Gut 2017;66(03):429–437
78 Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013;341(6150):124124
79 Jiao N, Baker SS, Chapa-Rodriguez A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut 2018;67(10):1881–1891
80 Puri P, Daita K, Joyce A, et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 2018;67(02):534–548
81 Bechmann LP, Kocabayoglu F, Sowa J-P, et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile-acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013;57(04):1394–1406
82 Ferslew BC, Xie G, Johnstone CK, et al. Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2015;60(11):3318–3328
83 Dasarathy S, Yang Y, McCullough AJ, Marczewski S, Bennett C, Kalhan SC. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2011;23(05):382–388
84 Mouzaki M, Wang AY, Bandmsra R, et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PloS One 2016;11(05):e0151829
85 Kalhan SC, Guo L, Edmison J, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011;60(03):404–413
86 Arana MM, Cortez-Pinto H, Costa A, et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2008;20(06):519–525
87 Lehy F, Franque S, Haas JT, et al. Bile acid alterations are associated with insulin resistance, but not with NASH, in obese subjects. J Clin Endocrinol Metab 2017;102(10):3783–3794
88 Hauesler RA, Astierraga B, Camasta S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes 2013;62(12):4184–4191
89 Watkins JB III, Sanders RA. Diabetes mellitus-induced alterations of hepatobiliary function. Pharmacol Rev 1995;47(01):1–23
90 Garcia-Marin JJ, Villanueva GR, Esteller A. Diabetes-induced cholestasis in the rat: possible role of hyperglycemia and hyperinsulinemia. Hepatology 1988;8(02):332–340
Carnovale CE, Roma MG, Monti JA, Rodriguez Garay EA. Studies on the mechanism of bile salt-independent bile flow impairment in streptozotocin-induced hepatotoxicity. Toxicology 1991;68(03):207–215

González J, Fevery J. Spontaneously diabetic biobreeding rats and impairment of bile acid-independent bile flow and increased biliary bilirubin, calcium and lipid secretion. Hepatology 1992;16(02):426–432

Cazanave S, Podtelezhnikov A, Jensen K, et al. The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci Rep 2017;7(01):17193

Min H-K, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012;15(05):655–674

Fickert P, Zollner G, Fuchsbichler A, et al. Ursodeoxycholic acid treatment in children with NAFLD. Liver Int 2018;38(02):342–349

Eren F, Kurt R, Erms F, Atog U, Imeryuz N, Yilmaz Y. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin Biochem 2012;45(09):655–658

Nobili V, Alisi A, Mosca A, et al. Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. Liver Int 2018;38(02):342–349

Schreuder TCMA, Marsman HA, Lenicek M, et al. The hepatic expression of FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010;298(03):G440–G445

Adiletta A, Ceccarelli S, Panera N, et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS One 2013;8(06):e67160

Sydor S, Best J, Messerschmidt I, et al. Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC. Clin Transl Gastroenterol 2020;11(03):e00131

Appleby RN, Moghul I, Khan S, et al. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: a prospective observational study. PLoS One 2019;14(01):e0211348

Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499(7456):97–101

Lelouvier B, Servant F, Païssé S, et al. Changes in blood microbiota composition associated with liver fibrosis in obese patients: a pilot analysis. Hepatology 2016;64(04):2015–2027

Zollner G, Fickert P, Zenz R, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001;33(03):633–646

Zhang Y, Li F, Patterson AD, et al. Abcb11 deficiency induces cholestasis coupled to impaired β-fatty acid oxidation in mice. J Biol Chem 2012;287(29):24784–24794

Zhong G, Jiang Y, Shi H, et al. FGF19 reduces fibrosis development in the obese Zucker rat. J Hepatol 2005;43(06):2397–2401

Han CY. Update on FXR biology: promising therapeutic target? Front Pharmacol 2018;9:1382

Li YTY, Swales KE, Thomas GJ, et al. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice. J Lipid Res 2009;50(06):1090–1096

Habruch E, Miyazaki-Anzai S, Hahn U, et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (−/−) mice. J Pharmacol Exp Ther 2012;343(03):556–567

Le BYT, Swales KE, Thomas GJ, Warner BD, Bishop-Bailey D. Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 2007;27(12):2606–2611

Gai Z, Gui T, Hiller C, Kullak-Ublick GA. Farnesoid X receptor protects against kidney injury in uninephrectomized obese mice. J Biol Chem 2016;291(05):2397–2411

Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice. J Lipid Res 2009;50(06):1090–1096

Hambruch E, Miyazaki-Anzai S, Hahn U, et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (−/−) mice. J Pharmacol Exp Ther 2012;343(03):556–567

Han CY. Update on FXR biology: promising therapeutic target? Int J Mol Sci 2018;19(07):E2069

Danic M, Stanimirov B, Pavlović N, et al. Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome. Front Pharmacol 2018;9:1382

Mudalier S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145(03):574.e1–82.e1

Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH

Harrison SA, Neff G, Guy CD, et al. Efficacy and safety of alfafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology 2021;160(01):219.e1–231.e1

Hirschfield GM, Chazouillères O, Drenth JP, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol 2019;70(03):483–493

Harrison SA, Abdelmalek MF, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2018;391(10126):1174–1185

Harrison SA, Trotter JF, Abdelmalek MF, et al. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol 2019;70(04):735–744

Fang S, Shu JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015;21(02):159–165

Xie C, Jiang C, Shi J, et al. An intestinal farnesoid X receptor-ceramide signaling axis modulates hepatic glucose homeostasis in mice. Diabetes 2017;66(03):613–626

Mueller M, Thorell A, Claudet T, et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol 2015;62(06):1398–1404

Boku VU, Kuzmitskaya-Nikolaeva IA, Naruta EE, Lukivskaya OY, Kirko SN, Tauschel H-D. Ursodeoxycholic acid dose-dependently improves liver injury in rats fed a methionine- and choline-deficient diet. Hepatol Res 2011;41(07):647–659

Wang W, Zhao J, Gui W, et al. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol 2018;175(03):469–484

Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006;313(5790):1137–1140

Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996;23(06):1464–1467

Leuschner UHF, Lindenthal B, Herrmann G, et al; NASH Study Group. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52(02):472–479

Lindor KD, Kowdiey KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39(03):770–778

Dufour J-F, Oneta CM, Convers J-J, et al; Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006;4(12):1537–1543

Ratziu V, de Ledinghen V, Oberti F, et al; FRESGUN. A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011;54(05):1011–1019

Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 2010;59(08):1899–1905

Pols TWH, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 2011;54(06):1263–1272

Watanabe M, Houten SM, Matakai C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006;439(7075):484–489

Roth JD, Feigh M, Veidal SS, et al. INT-767 improves histopathological features in a diet-induced oob/oob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol 2018;24(02):195–210

Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009;10(03):167–177

Hodge RJ, Lin J, Vasist Johnson LS, Gould EP, Bowers GD, Nunex DSJB-756050 Project Team. Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes. Clin Pharmacol Drug Dev 2013;2(03):213–222
Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H, Yoshiha M. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun 2007;354(01):154–159

Casaburi I, Avena P, Lanzino M, et al. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cell proliferation. Cell Cycle 2012;11(14):2699–2710

Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R, Häussinger D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 2009;50(03):861–870

Li T, Holmstrom SR, Kir S, et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol 2011;25(06):1066–1071

Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005;25(10):2020–2030

Tsuji Y, Kaji K, Kitade M, et al. Bile acid sequestrant, sevelamer ameliorates hepatic fibrosis with reduced overload of endogenous lipopolysaccharide in experimental nonalcoholic steatohepatitis. Microorganisms 2020;8(06):E925

Takahashi S, Luo Y, Ranjit S, et al. Bile acid sequestrant reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice. J Biol Chem 2020;295(14):4733–4747

Le T-A, Chen J, Changchien C, et al; San Diego Integrated NAFLD Research Consortium (SINC) Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012;56(03):922–932

Potthoff MJ, Potts A, He T, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol 2013;304(04):G371–G380

Rao A, Kosters A, Mells JE, et al. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med 2016;8(357):357ra122

Newsome PN, Palmer M, Freilich B, et al; Volixibat in Adults study group. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. J Hepatol 2020;73(02):231–240

Karpen SJ, Kelly D, Mack C, Stein P. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int 2020;14(05):677–689